Charts UCB

Stocks

UCB

BE0003739530

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 17/06/2026 BST			5-day change	1st Jan Change
252.40 ^EUR	+0.96%		-4.54%	+5.78%

06-17	UCB Publishes Data Demonstrating Positive Impact Of Kygevvi In Patients With Thymidine Kinase 2 Deficiency	CI
06-17	UCB SA completed the acquisition of Candid Therapeutics, Inc. from Vida Ventures Advisors, LLC and Two River Group Holdings, LLC.	CI

Chart: Technical Analysis

ProRealTime Chart

Technical analysis trends

	Short Term	Mid-Term	Long Term
Trend	Bullish	Neutral	Neutral
Resistance	274.9	285.4	279.5
Spread/Res.	-8.18%	-11.56%	-9.70%
Spread/Supp.	+1.65%	+11.58%	+36.80%
Support	248.3	226.2	184.5

MarketScreener's Technical Analysis Ratings

Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!